PASG

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Wall Street analysts forecast PASG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PASG is 40.33 USD with a low forecast of 21.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Passage Bio Inc revenue for the last quarter amounts to -8.66M USD, decreased -45.59 % YoY.

Passage Bio Inc. EPS for the last quarter amounts to -4853000.00 USD, decreased -35.01 % YoY.

Passage Bio Inc (PASG) has 60 emplpoyees as of January 07 2026.

Today PASG has the market capitalization of 58.68M USD.